Literature DB >> 20599975

Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia.

Jonathan Wills1, Jessica Jones, Thomas Haggerty, Valeriy Duka, Jeffrey N Joyce, Anita Sidhu.   

Abstract

Parkinson's disease (PD), a progressive neurodegenerative disease, results in abnormal accumulation of insoluble alpha-synuclein (alpha-Syn) in dopaminergic neurons. Here we examined tauopathic changes and the alpha-Syn/p-GSK-3beta/proteasome pathway in postmortem striata and inferior frontal gyri (IFG) from patients with PD and PD with dementia (PDD). In both PD and PDD, alpha-Syn levels were high, especially the insoluble form of this protein; in PDD, insoluble alpha-Syn levels were persistently higher than PD across both brain regions. Levels of p-GSK-3beta phosphorylated at Tyr 216, which hyperphosphorylates Tau to produce toxic pathological forms of p-Tau, were higher in striata of both PD and PDD compared to controls, but were unaltered in IFG. While proteasomal activity was unchanged in striatum of PD and PDD, such activity was diminished in the IFG of both PD and PDD. A decrease in 19S subunit of the proteasomes was seen in IFG of PDD, while lower levels of 20S subunits were seen in striatum and IFG of both PD and PDD patients. Parkin levels were similar in PD and PDD, suggesting lack of involvement of this protein. Most interestingly, tauopathic changes were noted only in striatum of PD and PDD, with increased hyperphosphorylation seen at Ser262 and Ser396/404; increases in Ser202 levels were seen only in PD but not in PDD striatum. We were unable to detect any tauopathy in IFG in either PD or PDD despite increased levels of alpha-Syn, and decreased proteasomal activity, and is probably due to lack of increase in p-GSK-3beta in IFG. Unlike Alzheimer's disease where tauopathy is more globally observed in diverse brain regions, our data demonstrates restricted expression of tauopathy in brains of PD and PDD, probably limited to dopaminergic neurons of the nigrostriatal region. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20599975      PMCID: PMC2922478          DOI: 10.1016/j.expneurol.2010.06.017

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  43 in total

1.  Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha-synucleinopathies.

Authors:  G Muntané; E Dalfó; A Martinez; I Ferrer
Journal:  Neuroscience       Date:  2008-02-05       Impact factor: 3.590

2.  Alpha-synuclein-positive structures in cases with sporadic Alzheimer's disease: morphology and its relationship to tau aggregation.

Authors:  Y Arai; M Yamazaki; O Mori; H Muramatsu; G Asano; Y Katayama
Journal:  Brain Res       Date:  2001-01-12       Impact factor: 3.252

3.  Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: role of D3 and not D2 receptors.

Authors:  J N Joyce; H L Ryoo; T B Beach; J N Caviness; Mark Stacy; E V Gurevich; Mark Reiser; C H Adler
Journal:  Brain Res       Date:  2002-11-15       Impact factor: 3.252

4.  Lewy body variant of Alzheimer's disease and Alzheimer's disease: a comparative immunohistochemical study.

Authors:  G M Szpak; E Lewandowska; W Lechowicz; E Bertrand; T Wierzba-Bobrowicz; E Gwiazda; E Pasennik; E Kosno-Kruszewska; W Lipczyńska-Lojkowska; A Bochyńska; U Fiszer
Journal:  Folia Neuropathol       Date:  2001       Impact factor: 2.038

5.  Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease.

Authors:  P M Mattila; J O Rinne; H Helenius; D W Dickson; M Röyttä
Journal:  Acta Neuropathol       Date:  2000-09       Impact factor: 17.088

6.  GSK3B polymorphisms alter transcription and splicing in Parkinson's disease.

Authors:  John B J Kwok; Marianne Hallupp; Clement T Loy; Daniel K Y Chan; Jean Woo; George D Mellick; Daniel D Buchanan; Peter A Silburn; Glenda M Halliday; Peter R Schofield
Journal:  Ann Neurol       Date:  2005-12       Impact factor: 10.422

7.  Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models.

Authors:  Tetyana Duka; Valeriy Duka; Jeffrey N Joyce; Anita Sidhu
Journal:  FASEB J       Date:  2009-04-15       Impact factor: 5.191

8.  Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes.

Authors:  C F Lippa; H Fujiwara; D M Mann; B Giasson; M Baba; M L Schmidt; L E Nee; B O'Connell; D A Pollen; P St George-Hyslop; B Ghetti; D Nochlin; T D Bird; N J Cairns; V M Lee; T Iwatsubo; J Q Trojanowski
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

9.  Comparative analyses of alpha-synuclein expression levels in rat brain tissues and transfected cells.

Authors:  Christophe Wersinger; Melanie Banta; Anita Sidhu
Journal:  Neurosci Lett       Date:  2004-03-25       Impact factor: 3.046

10.  Interleukin-1 mediates Alzheimer and Lewy body pathologies.

Authors:  W Sue T Griffin; Ling Liu; Yuekui Li; Robert E Mrak; Steven W Barger
Journal:  J Neuroinflammation       Date:  2006-03-16       Impact factor: 8.322

View more
  81 in total

1.  GSK-3β dysregulation contributes to parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synuclein.

Authors:  J J Credle; J L George; J Wills; V Duka; K Shah; Y-C Lee; O Rodriguez; T Simkins; M Winter; D Moechars; T Steckler; J Goudreau; D I Finkelstein; A Sidhu
Journal:  Cell Death Differ       Date:  2014-11-14       Impact factor: 15.828

2.  Ironing out tau's role in parkinsonism.

Authors:  Jeannette N Stankowski; Valina L Dawson; Ted M Dawson
Journal:  Nat Med       Date:  2012-02-06       Impact factor: 53.440

3.  3,4-Dihydroxyphenylacetaldehyde-Induced Protein Modifications and Their Mitigation by N-Acetylcysteine.

Authors:  Yunden Jinsmaa; Yehonatan Sharabi; Patti Sullivan; Risa Isonaka; David S Goldstein
Journal:  J Pharmacol Exp Ther       Date:  2018-04-26       Impact factor: 4.030

4.  α-Synuclein modifies mutant huntingtin aggregation and neurotoxicity in Drosophila.

Authors:  Gonçalo M Poças; Joana Branco-Santos; Federico Herrera; Tiago Fleming Outeiro; Pedro M Domingos
Journal:  Hum Mol Genet       Date:  2014-12-01       Impact factor: 6.150

Review 5.  Changes of cerebrospinal fluid Aβ42, t-tau, and p-tau in Parkinson's disease patients with cognitive impairment relative to those with normal cognition: a meta-analysis.

Authors:  Xiaohui Hu; Yan Yang; Daokai Gong
Journal:  Neurol Sci       Date:  2017-08-14       Impact factor: 3.307

Review 6.  Challenges of multimorbidity of the aging brain: a critical update.

Authors:  Kurt A Jellinger; Johannes Attems
Journal:  J Neural Transm (Vienna)       Date:  2014-08-05       Impact factor: 3.575

Review 7.  Autophagy in Parkinson's Disease.

Authors:  Xu Hou; Jens O Watzlawik; Fabienne C Fiesel; Wolfdieter Springer
Journal:  J Mol Biol       Date:  2020-02-13       Impact factor: 5.469

Review 8.  Interactions Between α-Synuclein and Tau Protein: Implications to Neurodegenerative Disorders.

Authors:  Xuling Li; Simon James; Peng Lei
Journal:  J Mol Neurosci       Date:  2016-09-15       Impact factor: 3.444

Review 9.  Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease.

Authors:  Cassia R Overk; Eliezer Masliah
Journal:  Biochem Pharmacol       Date:  2014-01-21       Impact factor: 5.858

10.  From model system to clinical medicine: pathophysiologic links of common proteinopathies.

Authors:  Pamela J McMillan; James B Leverenz
Journal:  Alzheimers Res Ther       Date:  2010-09-17       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.